Take Your Trading To The Next Level. Get Started Here!
+1 (949) 514 8188
Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
More convenient form of breakthrough Alzheimer’s drug Leqembi shows promising results in study
Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Archives
Categories
Archives
Recent Posts
Meta
Categories
Calender